B
Bramah N. Singh
Researcher at University of California, Los Angeles
Publications - 285
Citations - 17778
Bramah N. Singh is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Amiodarone & Sotalol. The author has an hindex of 63, co-authored 285 publications receiving 17380 citations. Previous affiliations of Bramah N. Singh include Zagazig University & City of Hope National Medical Center.
Papers
More filters
Journal ArticleDOI
Rhythm control versus rate control for atrial fibrillation and heart failure
Denis Roy,Mario Talajic,Stanley Nattel,D. George Wyse,Paul Dorian,Kerry L. Lee,Martial G. Bourassa,J. Malcolm,O. Arnold,Alfred E. Buxton,A. John Camm,Stuart J. Connolly,Marc Dubuc,Anique Ducharme,Peter G. Guerra,Stefan H. Hohnloser,Jean Lambert,Jean-Yves Le Heuzey,Ole Pedersen,Jean-Lucien Rouleau,Bramah N. Singh,Lynne W. Stevenson,William G. Stevenson,Bernard Thibault,Albert L. Waldo +24 more
TL;DR: In patients with atrial fibrillation and congestive heart failure, a routine strategy of rhythm control does not reduce the rate of death from cardiovascular causes, as compared with a rate-control strategy.
Journal ArticleDOI
Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.
Steven N. Singh,Ross D. Fletcher,Susan G. Fisher,Bramah N. Singh,H D Lewis,Prakash Deedwania,Barry M. Massie,Cindy Colling,D Lazzeri +8 more
TL;DR: Although amiodarone was effective in suppressing ventricular arrhythmias and improving ventricular function, it did not reduce the incidence of sudden death or prolong survival among patients with heart failure, except for a trend toward reduced mortality among those with nonischemic cardiomyopathy.
Journal ArticleDOI
Verapamil: A Review of its Pharmacological Properties and Therapeutic Use
TL;DR: Experimental and clinical data suggest that verapamil will become an important and safe addition to existing drug regimens, especially as an agent of choice for the short-term treatment of most cases of paroxysmal supraventricular tachycardias and in the maintenance of sinus rhythm following cardioversion of atrial fibrillation.
Journal ArticleDOI
Amiodarone versus sotalol for atrial fibrillation.
Bramah N. Singh,Steven N. Singh,Domenic J. Reda,X. Charlene Tang,Becky Lopez,Crystal L. Harris,Ross D. Fletcher,Satish C. Sharma,J. Edwin Atwood,Alan K. Jacobson,H. Daniel Lewis,Dennis W. Raisch,Michael D. Ezekowitz,Michael D. Ezekowitz +13 more
TL;DR: Amiodarone is superior for maintaining sinus rhythm, but both drugs have similar efficacy in patients with ischemic heart disease, and sustained Sinus rhythm is associated with an improved quality of life and improved exercise performance.
Journal ArticleDOI
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter
Bramah N. Singh,Stuart J. Connolly,Denis Roy,Peter R. Kowey,Alessandro Capucci,David Radzik,Etienne Aliot,Stefan H. Hohnloser +7 more
TL;DR: Dronedarone was significantly more effective than placebo in maintaining sinus rhythm and in reducing the ventricular rate during recurrence of arrhythmia.